Institution Directory

Clinical trials at Massachusetts General Hospital

Sites in Boston, MA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 6:41 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1478

Shown on this page

Current sort

Live official records

Conditions: Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
Interventions: LY4066434., Cetuximab, Nab paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Irinotecan, 5Fluorouracil, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 22
States / cities: Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 16 more

Conditions: Hereditary Hemorrhagic Telangiectasia, Arteriovenous Malformations, Telangiectasia, Epistaxis, GastroIntestinal Bleeding, Cerebral Arteriovenous Malformations, Vascular Malformation
Interventions: Not listed
Lead sponsor: Cure HHT; Other
Eligibility: Not listed
Enrollment: 10,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2033
U.S. locations: 16
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 13 more

Conditions: Invasive Breast Cancer, Triple Negative Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer, HER2-negative Breast Cancer
Interventions: Sacituzumab Govitecan, Pembrolizumab; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 5
States / cities: Boston, Massachusetts • Danvers, Massachusetts • Newton, Massachusetts

Conditions: Impaired Cognition, Chemo-brain, Breast Cancer
Interventions: Cognitive, functional and subjective assessments, MRI, PET Scan; Other · Device · Radiation
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 60 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts • Salem, Massachusetts

Conditions: Lung Cancer
Interventions: lobectomy, segmentectomy or wedge resection; Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2027
U.S. locations: 373
States / cities: Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 245 more

Conditions: Metastatic Breast Cancer
Interventions: PMD-026, fulvestrant; Drug
Lead sponsor: Phoenix Molecular Designs; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 10
States / cities: Gilbert, Arizona • Duarte, California • Irvine, California + 7 more

Conditions: Medulloblastoma
Interventions: Cisplatin, Cyclophosphamide, Laboratory Biomarker Analysis, Lomustine, Magnetic Resonance Imaging, Radiation Therapy, Vincristine, Vincristine Sulfate; Drug · Other · Procedure + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 3 Years to 21 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 173
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 134 more

Conditions: Familial Partial Lipodystrophy
Interventions: Metreleptin; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 13 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 7
States / cities: Birmingham, Alabama • Boca Raton, Florida • Boston, Massachusetts + 4 more

Conditions: Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC), Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), Neuroendocrine Carcinomas (NEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
Interventions: Peluntamig (PT217), Carboplatin + Etoposide, Paclitaxel., Atezolizumab, Lurbinectedin, Irinotecan (drug), Topotecan; Drug
Lead sponsor: Phanes Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 15
States / cities: Duarte, California • Los Angeles, California • Denver, Colorado + 11 more

Conditions: Functional Dyspepsia
Interventions: Sensory device, Skills Building, Health Education, Subsensory device; Device · Behavioral
Lead sponsor: Spaulding Rehabilitation Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Lung Cancer (NSCLC), Lung Cancer Non-Small Cell Cancer (NSCLC), Lung Cancer (Non-Small Cell), Lung Cancer - Non Small Cell, Lung Cancer Non Small Cell, Genomic Alterations
Interventions: Ivonescimab, carboplatin, pemetrexed; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Lung Cancer, EGFR Gene Mutation
Interventions: Circulating Tumor DNA (ctDNA) Assay; Device
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 40 Years to 80 Years
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 6
States / cities: Boston, Massachusetts • Brighton, Massachusetts • Methuen, Massachusetts + 1 more

About this Massachusetts General Hospital institution page

What this page lists: ClinicalTrials.gov records that list Massachusetts General Hospital in Boston, MA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Massachusetts General Hospital

Filter and sort this campus

Live official records

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Comprehensive HHT Outcomes Registry of the United States (CHORUS)

Sacituzumab Govitecan In TNBC

Chemotherapy-induced Cognitive and Brain Changes in Older Adults With Breast Cancer

Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer

Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer

Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma

Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

Synergistic Gut-brain Axis Modulation Via Vagal Stimulation and Support Therapy in Functional Dyspepsia

Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC

EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations

About this Massachusetts General Hospital institution page